{
    "id": "dbpedia_1551_2",
    "rank": 64,
    "data": {
        "url": "https://cordis.europa.eu/project/id/848146/de",
        "read_more_link": "",
        "language": "en",
        "title": "A high-dimensional approach for unwinding immune-metabolic causes of cardiovascular disease-depression multimorbidities",
        "top_image": "https://cordis.europa.eu/projects/icons/logo_h2020_big.jpg",
        "meta_img": "https://cordis.europa.eu/projects/icons/logo_h2020_big.jpg",
        "images": [
            "https://cordis.europa.eu/build/images/preset-ec/logo/positive/logo-ec--de.svg",
            "https://cordis.europa.eu/images/projects/icons/logo-h2020.jpg",
            "https://cordis.europa.eu/build/images/preset-ec/logo/negative/logo-ec--de.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "TO_AITION",
            "A high-dimensional approach for unwinding immune-metabolic causes of cardiovascular disease-depression multimorbidities",
            "cardiovascular",
            "metabolic",
            "depression",
            "biomarkers",
            "inflammation",
            "H2020-EU.3.1.",
            "H2020",
            "SC1-BHC-01-2019",
            "",
            "Research & Development"
        ],
        "tags": null,
        "authors": [
            "CORDIS, cordis.europa.eu"
        ],
        "publish_date": "2024-06-03T14:40:12",
        "summary": "",
        "meta_description": "Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional...",
        "meta_lang": "de",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "CORDIS | European Commission",
        "canonical_link": "https://cordis.europa.eu/project/id/848146/de",
        "text": "Projektbeschreibung\n\nErforschung von Mechanismen des Auftretens von Depressionen und Herz-Kreislauf-Erkrankungen als Begleiterkrankungen\n\nDepressionen gehen sehr häufig mit Herz-Kreislauf-Erkrankungen einher und erhöhen das Risiko, eine Herz-Kreislauf-Erkrankung zu entwickeln, sowie von Akutereignissen und Sterblichkeit erheblich. Das gilt besonders bei Frauen. Folglich stellen sie ein soziales und wirtschaftliches Problem dar, das sich auf das Leben von Patientinnen und Patienten auswirkt und zu höheren Gesundheitsausgaben führt. Allerdings sind die Mechanismen und die Progression der Erkrankung noch immer unbekannt. Das EU-finanzierte Projekt TO_AITION arbeitet mit der Hypothese, dass Fehlregulationen des Immunsystems und Stoffwechsels aufgrund von Risikofaktoren der Genetik, des Lebensstils und der Umwelt sich auf Mechanismen des Immunsystems auswirken, die zu mit Herz-Kreislauf-Erkrankungen assoziierten Depressionen führen. Das Projekt wird grundlegende vorklinische und klinische Forschung betreiben und dabei datengestützte Strategien anwenden, um die Mechanismen des Immunsystems und Stoffwechsels festzustellen und zu beschreiben, die für Depressionen und Herz-Kreislauf-Erkrankungen als Begleiterkrankungen verantwortlich sind. Auf diese Weise sollen die Diagnose und die Bewältigung der Krankheit verbessert werden.\n\nZiel\n\nDepression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional risk factors, and constitutes an enormous socioeconomic burden in terms of morbidity, mortality and healthcare costs. Still, the patients at risk, disease trajectories and causative mechanisms involved remain unknown.\n\nTO_AITION addresses the hypothesis that immune-metabolic dysregulation, occurring as a result of genetic, lifestyle and environmental risk factors ‘training’ innate immunity, drives low grade systemic inflammation leading to the development of CVD-depression comorbidity.\n\nIt integrates basic (cell models, immune-metabolic mechanisms, myeloid cell reprogramming), preclinical (animal models, CRISPR genome editing) and clinical (longitudinal cohorts with comprehensive existing data) research, in order to characterise immune-metabolic mechanisms driving CVD-depression comorbidity. Both hypothesis and data-driven strategies will be employed to address causality, focusing on genetic, epigenetic, transcriptional, metabolic and other disturbances leading to the development of comorbidity. Drug-drug interactions and their effects on causative mechanisms and disease trajectories will also be determined. Pathways identified will be evaluated in cell-based and animal models to prove their causal role and obtain mechanistic insight. Finally, new risk models will be developed, and relevant regulatory, cost-effectiveness and feasibility issues addressed. Effective patient-oriented awareness actions, dissemination, exploitation and management activities are also provisioned.\n\nTO_AITION will therefore rationally change our current understanding of the causative mechanisms driving CVD-depression comorbidity, unravelling patients’ complexity and improving their diagnosis, monitoring and management.\n\nAufforderung zur Vorschlagseinreichung\n\nH2020-SC1-BHC-2018-2020\n\nAndere Projekte für diesen Aufruf anzeigen\n\nUnterauftrag\n\nH2020-SC1-2019-Two-Stage-RTD\n\nKoordinator\n\nIDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON\n\nNetto-EU-Beitrag\n\n€ 879 343,75\n\nGesamtkosten\n\n€ 879 343,75"
    }
}